Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants

NCT07258745 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

213

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

BIOLOGICAL: SKYRIZI
BIOLOGICAL: SKYRIZI
BIOLOGICAL: CKD-704

Sponsor

Chong Kun Dang Pharmaceutical